Full Breakdown
WHO Criticizes US-Funded Hepatitis B Vaccine Trial in Guinea-Bissau
2/15/2026, 8:11:42 PM
Overview of the Controversy
The World Health Organization (WHO) has condemned a US-funded hepatitis B vaccine trial involving newborns in Guinea-Bissau, labeling it as “unethical.” The trial, which aimed to enroll approximately 14,000 infants, proposed administering the hepatitis B vaccine to one group at birth while delaying the vaccine for another group until six weeks. The WHO expressed concerns that withholding a proven life-saving intervention from some newborns could expose them to "potentially irreversible harm."
Scientific and Ethical Concerns
The WHO's criticism centers on the trial's scientific justification, ethical safeguards, and adherence to established research standards. The organization emphasized that the hepatitis B birth dose vaccine has been utilized for over three decades in more than 115 countries and is critical for preventing mother-to-child transmission of the virus. According to the WHO, infection at birth is the most common route for chronic hepatitis B infection, with about 90% of infected newborns becoming lifelong carriers. The WHO recommends that all newborns receive the hepatitis B vaccine within 24 hours of birth.
Background of the Trial
The trial was funded by the US Centers for Disease Control and Prevention (CDC) under the leadership of Health Secretary Robert F. Kennedy Jr. It was intended to explore the broader health effects of the hepatitis B vaccine. However, the CDC's funding decision has faced backlash, particularly after an advisory panel appointed by Kennedy voted to stop recommending universal hepatitis B vaccination for newborns in the United States. Critics have pointed to the controversial history of the Danish researchers leading the trial, Christine Stabell Benn and Peter Aaby, who have been scrutinized for their past research practices.
Public Reaction and Suspension of the Trial
Following public outrage and condemnation from health experts, the Guinea-Bissau government suspended the trial last month. Former Guinea-Bissau health minister Magda Robalo criticized the study, stating, “Guinea-Bissauans are not guinea pigs.” The WHO reiterated that trials withholding proven treatments are only acceptable when no effective intervention exists, a condition not met in this case.
Future Implications
Guinea-Bissau currently administers the hepatitis B vaccine at six weeks but plans to transition to a birth dose nationwide by 2028, with support from the WHO. The organization aims to accelerate this transition in light of the ongoing hepatitis B prevalence in the country, where over 12% of adults are estimated to live with chronic infection.
Verbatim Quotes
- “In its current form, and based on publicly available information, the trial is inconsistent with established ethical and scientific principles,” — WHO Statement
- “Giving a proven life-saving intervention to some newborns but not others expose them to potentially irreversible harm,” — WHO Statement
- “Guinea-Bissauans are not guinea pigs.” — Magda Robalo, Former Guinea-Bissau Health Minister
Conclusion
The WHO's condemnation of the US-funded hepatitis B vaccine trial highlights significant ethical and scientific concerns regarding the treatment of vulnerable populations in medical research. The suspension of the trial reflects the critical need for adherence to established health standards and the protection of public health, particularly in regions with high rates of infectious diseases.
